Clinical Trial Update: Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating neoadjuvant and adjuvant sintilimab plus cetuximab in resectable locally advanced oral and oropharyngeal squamous cell carcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• Sintilimab (sintilimab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING